Klivira
Request demo

Optimizing Rheumatology Prior Authorization Automation

Klivira offers advanced rheumatology prior authorization automation, specifically designed to navigate the complexities of biologic and specialty drug approvals.

Rheumatology practices face a disproportionate burden of prior authorizations, driven by the high cost and chronic nature of advanced therapies for conditions like rheumatoid arthritis, psoriatic arthritis, and lupus. Managing these PAs efficiently is critical for patient access to care and maintaining revenue cycle integrity. Klivira provides a specialized solution to transform this challenge into a streamlined operational process.

The High-Volume PA Categories in Rheumatology

Prior authorization in rheumatology is heavily concentrated on high-cost biologics and targeted synthetic DMARDs, which are central to managing chronic autoimmune diseases. These therapies frequently trigger PA requirements due to their expense and the need for stringent clinical oversight, making them a primary focus for automation. This includes treatments for conditions such as RA, PsA, AS, and lupus.

Key PA-Triggering Therapies and Procedures

  • TNF-alpha inhibitors (e.g., adalimumab, etanercept, infliximab, certolizumab, golimumab)
  • Non-TNF biologics and targeted synthetic DMARDs (e.g., IL-6, IL-17, IL-23 inhibitors, B-cell depletion, JAK inhibitors)
  • Specialty drugs for specific indications (e.g., anifrolumab, belimumab, tildrakizumab, ustekinumab)
  • Advanced imaging for inflammatory arthritis assessment (e.g., MRI, ultrasound-guided injections)
  • DEXA scans for osteoporosis management in chronic-steroid patients

Essential Documentation for Rheumatology PAs

  • Diagnosis documentation with disease-specific criteria (e.g., 2010 ACR/EULAR for RA, CASPAR for PsA, 2019 EULAR/ACR for SLE) [acr-treatment-guidelines]
  • Disease activity assessment scores (e.g., DAS28, CDAI, SDAI for RA; PASI/BSA for psoriasis; BASDAI for AS; SLEDAI for SLE)
  • Documentation of prior conventional DMARD trial and response (e.g., methotrexate, sulfasalazine) [acr-treatment-guidelines]
  • Evidence of step therapy compliance, including biosimilar substitution mandates
  • Completion of required screenings (e.g., TB, hepatitis B/C, immunization status) prior to immunosuppressive biologic initiation

Common Denial Reasons in Rheumatology PAs

  • Failure to document required step therapy completion or specific prior agent trial
  • Denial of brand TNF inhibitor when a biosimilar is mandated for initial trial
  • Absence of documented disease activity scores (e.g., DAS28, CDAI, PASI)
  • Insufficient duration of conservative care or initial csDMARD trial
  • Gaps in screening documentation (e.g., TB, hepatitis, immunization)
  • Off-indication use without explicit payer policy support for the requested condition

Klivira's Tailored Approach for Rheumatology Prior Authorization Automation

Klivira’s platform is engineered to address the specific nuances of rheumatology prior authorization. Our system incorporates ACR-guideline-aware policy logic for precise step therapy sequencing and handles the variability of biosimilar substitution mandates across different payers. This targeted functionality streamlines the PA process, reducing administrative burden and improving approval rates.

Klivira's Rheumatology-Specific Capabilities

  • ACR-guideline-aware policy logic for indication-specific step therapy sequencing [acr-treatment-guidelines]
  • Dynamic biosimilar substitution routing that adapts to per-payer mandates and brand-to-biosimilar conversion workflows
  • Automated periodic re-authorization workflows for chronic biologic treatments, ensuring continuous response documentation
  • Intelligent medical-vs-pharmacy benefit split routing for the same agent based on administration mode and payer policy
  • Specialized pediatric PA flows incorporating weight-based dosing and pediatric guideline criteria

Frequently asked questions

How does Klivira manage complex step therapy requirements for rheumatology biologics?

Klivira integrates ACR-guideline-aware policy logic to automatically sequence step therapy requirements based on specific indications. Our system accounts for prior conventional DMARD trials and navigates biosimilar substitution mandates, ensuring that all necessary steps are documented and followed per payer rules.

Can Klivira help with re-authorizations for chronic rheumatology treatments?

Yes, Klivira includes a dedicated workflow for periodic re-authorizations of chronic biologic treatments. The platform prompts for and helps compile continuous disease response documentation, such as updated disease activity scores, to support ongoing approval needs.

How does Klivira handle the distinction between medical and pharmacy benefit drugs in rheumatology?

Klivira's platform is designed to intelligently route prior authorizations based on whether a rheumatology drug falls under the medical or pharmacy benefit. This ensures that the correct PA pathway is followed, even for agents that may switch benefit types depending on the administration method or payer-specific policy.

Does Klivira assist with documenting disease activity scores like DAS28 or PASI?

Yes, Klivira's system is built to facilitate the inclusion of critical disease activity assessments such as DAS28, CDAI, SDAI, PASI, and BASDAI. The platform helps ensure these scores, which are frequently required by payers, are accurately documented and submitted with the PA request to prevent denials.

Is Klivira equipped to handle pediatric rheumatology prior authorizations?

Absolutely. Klivira offers specialized PA flows for pediatric rheumatology cases. These flows incorporate specific considerations such as weight-based dosing requirements and adherence to pediatric guideline criteria, addressing the unique complexities of PA for younger patients.

Related coverage

Optimizing prior auth workflows

Optimizing prior auth coverage by state

Optimizing prior authorization by drug

Optimizing prior authorization by procedure

Ready to automate prior auth for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo